Clinical trial of autologous adiose tissue derived stromal cell therapy for ischemic heart failure

Clinical trial of autologous adiose tissue derived stromal cell therapy for ischemic heart failure - Heart regeneration therapy by autologous Adipose Tissue Derived Stromal Cells

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009066

Enrollment

Registered

2012-10-09

Start date

2012-10-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart failure

Interventions

Intracoronary administration of autologus adipose tissue derived regenerative cells.(3.33X10^5cell/Kg or 6.6X10^5cell/Kg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Heart failure patients occured by prior ischemic event whose ejection fraction must be less than 40%.

Exclusion criteria

Exclusion criteria: *Complicated severe other organ disease. *Patient with malignancy. *History of chemotherapy or irradiation within 4 weeks. *Patient with immunodeficiency *Pregnancy or possibility of pregnancy *Candidate who are judged to be not applicable to this study by doctors.

Design outcomes

Primary

Measure	Time frame
Assesment of safety in the context of adverse events defined in the implementation protocol.	—

Countries

Japan

Contacts

Public ContactMasayuki Takamura

Kanazawa University Hospital Department of Cardiology

mtakamura@m-kanazawa.jp076-265-2238

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026